Q4 EPS Estimates for AstraZeneca Raised by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Investment analysts at Zacks Research lifted their Q4 2026 earnings per share estimates for AstraZeneca in a research note issued on Thursday, September 11th. Zacks Research analyst Team now expects that the company will earn $1.35 per share for the quarter, up from their prior estimate of $1.30. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same period last year, the company earned $1.24 earnings per share. The company’s revenue was up 16.1% on a year-over-year basis.

Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $77.56 on Monday. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $82.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The business has a fifty day moving average price of $76.27 and a 200-day moving average price of $72.97. The company has a market capitalization of $240.54 billion, a PE ratio of 29.16, a PEG ratio of 1.43 and a beta of 0.37.

Institutional Investors Weigh In On AstraZeneca

Several institutional investors have recently modified their holdings of AZN. Goldman Sachs Group Inc. boosted its position in shares of AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after buying an additional 3,224,251 shares during the last quarter. Fayez Sarofim & Co boosted its position in shares of AstraZeneca by 173.4% during the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after buying an additional 2,376,032 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in shares of AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after buying an additional 2,307,047 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of AstraZeneca by 2,389.9% during the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after buying an additional 1,961,764 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of AstraZeneca by 406.9% during the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after buying an additional 1,621,974 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.